TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
1.680
+0.050 (3.07%)
At close: Oct 13, 2026, 4:00 PM EDT
1.770
+0.090 (5.36%)
After-hours: Oct 13, 2026, 7:46 PM EDT
TransCode Therapeutics Employees
TransCode Therapeutics had 12 employees as of December 31, 2025. The number of employees increased by 5 or 71.43% compared to the previous year. That makes TransCode Therapeutics the 39,763rd largest employer in the world and 5,975th in the United States.
Employees
12
Change (1Y)
5
Growth (1Y)
71.43%
Revenue / Employee
n/a
Profits / Employee
-$3,857,068
Market Cap
28.44M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 12 | 5 | 71.43% | 12 | 0 |
| Dec 31, 2024 | 7 | -3 | -30.00% | 7 | 0 |
| Sep 30, 2024 | 8 | -2 | -20.00% | 8 | 0 |
| Dec 31, 2023 | 10 | -9 | -47.37% | 10 | 0 |
| Dec 31, 2022 | 19 | 10 | 111.11% | 19 | 0 |
| Dec 31, 2021 | 9 | 3 | 50.00% | 8 | 1 |
| Sep 30, 2021 | 7 | 1 | 16.67% | 7 | 0 |
| Jun 30, 2021 | 6 | 0 | - | 2 | 4 |
| Mar 31, 2021 | 6 | 0 | - | 2 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| IGC Pharma | 70 |
| NextCure | 40 |
| Quince Therapeutics | 38 |
| Actinium Pharmaceuticals | 27 |
| BriaCell Therapeutics | 16 |
| Context Therapeutics | 15 |
| NanoViricides | 7 |
RNAZ News
- 14 hours ago - Natera, Transcode to collaborate on Phase 2a trial of TTX-MC138 - TheFly
- 14 hours ago - Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer - Business Wire
- 11 days ago - TransCode Therapeutics Slides: Investor presentation - Filings
- 15 days ago - Transcode Therapeutics reports updated results from Phase 1a TTX-MC138 trial - TheFly
- 15 days ago - TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up - PRNewsWire
- 21 days ago - Transcode Therapeutics announces patent advancements in Australia and Japan - TheFly
- 21 days ago - Transcode Therapeutics announces patent advancements in Australia and Japan - TheFly
- 21 days ago - TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology - PRNewsWire